Jason R Manro Selected Research

merestinib

1/2018	MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping.
10/2013	Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653, an inhibitor of several oncokinases, including MET.
8/2013	LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jason R Manro Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 08/2013
2	Lung Neoplasms (Lung Cancer) 01/2021 - 01/2018
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2019 - 10/2013
2	Neoplasm Metastasis (Metastasis) 12/2014 - 10/2013
1	Polyploidy 12/2019
1	Aneuploidy (Aneuploid) 12/2019
1	Carcinoma (Carcinomatosis) 01/2018
1	Melanoma (Melanoma, Malignant) 01/2015
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2009
1	Shock 10/2006

Drug/Important Bio-Agent (IBA)

4	Phosphotransferases (Kinase)IBA 12/2019 - 05/2009
3	merestinibIBA 01/2018 - 08/2013
2	pembrolizumabIBA 01/2022 - 12/2019
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 05/2009
2	Adenosine Triphosphate (ATP)IBA 01/2021 - 08/2013
2	LY-2157299IBA 01/2018 - 01/2018
2	emibetuzumabIBA 01/2018 - 12/2014
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022
1	sintilimabIBA 01/2022
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2022
1	RamucirumabIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	durvalumabIBA 01/2022
1	B7-H1 AntigenIBA 01/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021
1	LY3214996IBA 01/2021
1	abemaciclibIBA 01/2021
1	LY3023414IBA 01/2021
1	Pemetrexed (MTA)FDA Link 12/2019
1	Folic Acid (Vitamin M)FDA LinkGeneric 12/2019
1	Protein Isoforms (Isoforms)IBA 12/2019
1	Carboplatin (JM8)FDA LinkGeneric 12/2019
1	Biomarkers (Surrogate Marker)IBA 12/2019
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2018
1	AntigensIBA 01/2018
1	CaspasesIBA 01/2015
1	3- (9- fluoro- 2- (piperidin- 1- ylcarbonyl)- 1,2,3,4- tetrahydro(1,4)diazepino(6,7,1- hi)indol- 7- yl)- 4- imidazo(1,2- a)pyridin- 3- yl- 1H- pyrrole- 2,5- dioneIBA 01/2015
1	Glycogen Synthase (Synthase I)IBA 01/2015
1	Small Interfering RNA (siRNA)IBA 01/2015
1	CateninsIBA 01/2015
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 12/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2013
1	Gemcitabine FDA Link 10/2013
1	Cisplatin (Platino)FDA LinkGeneric 10/2013
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2013
1	Oncogene Proteins (Oncogene Protein)IBA 08/2013
1	LigandsIBA 08/2013
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 08/2013
1	c-Mer Tyrosine KinaseIBA 08/2013
1	tyrosine receptor (receptor, tyrosine)IBA 08/2013
1	AMPA Receptors (AMPA Receptor)IBA 10/2006
1	LY 404187IBA 10/2006
1	HarmalineIBA 10/2006

Therapy/Procedure

3	Therapeutics 01/2022 - 01/2018
2	Immunotherapy 12/2019 - 01/2018
1	Drug Therapy (Chemotherapy) 12/2019
1	Duration of Therapy 01/2018
1	Withholding Treatment 01/2018